The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock

Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lil

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

One of Cathie Wood's funds just sold some AtaiBeckley shares. It also bought some Compass Pathways s

MONSEY, N.Y., July 28, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is invest

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empir

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

HC Wainwright & Co. analyst Patrick R. Trucchio downgrades AtaiBeckley (NASDAQ:ATAI) from Buy

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Lulu's Fashion Lounge Holdings (NASDAQ:LVLU) retained Solomon Partners as its financial advisor and

Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psyched

Top Wall Street analysts changed outlook on top names. Check full changes on analyst ratings page. O

Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Ph

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforc

Jefferies analyst Andrew Tsai downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers th

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

AtaiBeckley is developing a promising depression treatment. Eli Lilly has long been a leader in neur

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a c

Canaccord Genuity analyst Sumant Kulkarni downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold a

NEW YORK, July 16, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & As

AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lill

CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history

Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea

Eli Lilly and Co (NYSE:LLY) on Thursday agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal t

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression ther

4:15pm: Semiconductor selloff Wall Street ended lower on Thursday, with semiconductor stocks leading

U.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, sto

U.S. stock futures declined on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices fell,

Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session

Eli Lilly and Company (NYSE:LLY) and AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceuti

JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7

AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire

Canaccord Genuity analyst Sumant Kulkarni maintains AtaiBeckley (NASDAQ:ATAI) with a Buy and rais

AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotec

The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarkedInclusion expands At

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates AtaiBeckley (NASDAQ:ATAI) with a B

AtaiBeckley (NASDAQ:ATAI) reported quarterly losses of $(0.08) per share which beat the analyst cons

Health officials explored restricting specific antidepressants among SSRI drugs-sources

https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex

AtaiBeckley reports Phase 2a data for EMP-01 in social anxiety, showing stronger symptom reduction a

At Day 43, EMP‑01 achieved a 38% reduction vs 15% on placebo (Hedges' g=0.84) on the patient-rep

AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump

Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer

Canaccord Genuity analyst Sumant Kulkarni maintains AtaiBeckley (NASDAQ:ATAI) with a Buy and rais

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump